Kopran

Why is Kopran Ltd falling/rising?

As of 04-Aug, Kopran Ltd's stock price is at 187.20, down 0.87%, and has underperformed the Sensex, which rose by 2.17%. Despite increased investor participation, the stock's negative trend and recent declines indicate ongoing struggles in its performance.

As of 04-Aug, Kopran Ltd's stock price is currently at 187.20, reflecting a decrease of 1.65 (-0.87%). The stock has been underperforming compared to the benchmark Sensex, which has increased by 2.17% over the past week while Kopran Ltd has fallen by 5.95%. Additionally, the stock has experienced a consecutive decline over the last two days, resulting in a total drop of 2.42% during this period.<BR><BR>Despite touching an intraday high of Rs 195.95 earlier in the day, the overall performance indicates a struggle, as the stock has not only underperformed its sector by 0.82% but also shows a negative trend in its short-term moving averages, being lower than the 5-day, 20-day, and 50-day averages. <BR><BR>Investor participation appears to be rising, with a significant increase in delivery volume of 13.11k on 03 Aug, which is up by 126.65% compared to the 5-day average. However, this increase in trading volume has not translated into a positive price movement, indicating that while more investors are participating, the sentiment surrounding the stock remains negative. <BR><BR>Overall, the combination of recent price declines, underperformance relative to the market, and the current trading dynamics contribute to the falling stock price of Kopran Ltd.

Which are the latest news on Kopran?

Should I buy, sell or hold Kopran Ltd?

When is the next results date for Kopran Ltd?

The next results date for Kopran Ltd is August 7, 2026.

The next results date for Kopran Ltd is scheduled for August 7, 2026.

How big is Kopran?

As of 10th June, Kopran Ltd has a market capitalization of 884.00 Cr, with recent net sales of 681.43 Cr and a net profit of 25.74 Cr. The company has shareholder's funds of 518.35 Cr and total assets of 844.01 Cr.

As of 10th June, Kopran Ltd has a market capitalization of 884.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Kopran reported Net Sales of 681.43 Cr and a Net Profit of 25.74 Cr.<BR><BR>For the latest annual period, the company has Shareholder's Funds of 518.35 Cr and Total Assets amounting to 844.01 Cr.

Who are in the management team of Kopran?

The management team of Kopran includes Surendra Somani (Executive Vice Chairman), Sunil Sodhani (Company Secretary), and several Independent Directors: Siddhan Subramanian, Sunita Banerji, Mamta Biyani, and Narayan Atal, along with Non-Executive Chairman Susheel Somani and Non-Executive Directors Adarsh Somani and Varun Somani. They oversee the company's operations and strategic direction.

The management team of Kopran includes the following individuals:<BR><BR>1. Surendra Somani - Executive Vice Chairman<BR>2. Sunil Sodhani - Company Secretary & Compliance Officer<BR>3. Siddhan Subramanian - Independent Director<BR>4. Sunita Banerji - Independent Director<BR>5. Mamta Biyani - Independent Director<BR>6. Narayan Atal - Independent Director<BR>7. Susheel Somani - Chairman (Non-Executive)<BR>8. Adarsh Somani - Non-Executive Director<BR>9. Varun Somani - Non-Executive Director<BR><BR>This team plays a crucial role in overseeing the company's operations and strategic direction.

Who are the peers of the Kopran?

Kopran's peers include Bajaj Healthcare, Fermenta Biotec, Themis Medicare, Bharat Parenter, Wanbury, Sigachi Industries, Anuh Pharma, Anlon Healthcare, Shree Ganesh Rem, and Remus Pharma. In terms of management risk, growth, capital structure, and returns, Sigachi Industries and Anuh Pharma show excellent ratings, while Kopran has average ratings and a 1-year return of -10.43%.

Peers: The peers of Kopran are Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Bharat Parenter., Wanbury, Sigachi Indust., Anuh Pharma, Anlon Healthcare, Shree Ganesh Rem, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sigachi Indust. and Anuh Pharma, while Average management risk is found at Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Bharat Parenter., Wanbury, Kopran, Anlon Healthcare, and Shree Ganesh Rem, and the rest. Growth is rated as Excellent for Anlon Healthcare, Good for Wanbury, while the rest, including Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Bharat Parenter., Kopran, Sigachi Indust., Anuh Pharma, and Shree Ganesh Rem, are rated Below Average. In terms of Capital Structure, Excellent ratings are given to Sigachi Indust. and Anuh Pharma, Good to Anlon Healthcare and Kopran, while Average is noted for Bharat Parenter. and Below Average for the remaining peers.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bharat Parenter. at 6.09%, while the lowest is Sigachi Indust. at -62.71%. Kopran's own 1-year return is -10.43%, which is higher than Sigachi Indust. but lower than Bharat Parenter. Additionally, peers with negative six-month returns include Sigachi Indust. and Remus Pharma.

What does Kopran do?

Kopran Ltd is a micro-cap pharmaceutical and biotechnology company focused on developing and manufacturing Penicillin and non-penicillin-based drugs. As of March 2026, it reported net sales of 234 Cr and a net profit of 19 Cr, with a market cap of INR 884 Cr.

Overview:<BR>Kopran Ltd is a pharmaceutical and biotechnology company specializing in the development and manufacturing of Penicillin and non-penicillin-based drugs, categorized as a micro-cap company.<BR><BR>History:<BR>Kopran Ltd was incorporated on April 26, 1958, and is a group company of Parijat Enterprises. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 234 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 19 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 884 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 34.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.64% <BR>Debt-Equity: 0.27 <BR>Return on Equity: 4.85% <BR>Price to Book: 1.67 <BR><BR>Contact Details:<BR>Address: Parijat House 1076, Dr E Moses Road Worli Mumbai Maharashtra : 400018 <BR>Tel: 91-22-43661111 <BR>Email: investors@kopran.com <BR>Website: http://www.kopran.com

Are Kopran Ltd latest results good or bad?

Kopran Ltd's latest Q4 FY26 results are strong, showing a net profit increase of over 102% quarter-on-quarter and a revenue growth of 35.77% year-on-year. However, concerns about the sustainability of this performance due to past volatility suggest caution for future outlook.

Kopran Ltd's latest results for Q4 FY26 indicate a strong performance, marking a significant recovery from previous quarters. The company reported a net profit of ₹18.87 crores, which is a remarkable increase of 102.03% quarter-on-quarter and 94.94% year-on-year. Additionally, revenue grew by 35.77% compared to the same quarter last year, reaching ₹234.02 crores, the highest in at least eight quarters.<BR><BR>The operating margin also improved significantly to 14.08%, the best performance in two years, reflecting better operational efficiency. However, while these results are encouraging, they come after a period of volatility, including a loss in the previous quarter. <BR><BR>Despite the positive indicators in the latest quarter, there are concerns regarding the sustainability of these improvements, given the company's history of fluctuating performance and modest return on equity. The overall sentiment is mixed; while the recent results are good, the underlying operational challenges and volatility raise questions about long-term stability. Therefore, while the latest results can be seen as good, caution is warranted regarding future performance.

How has been the historical performance of Kopran?

Kopran's historical performance shows steady sales growth from INR 359.50 crore in March 2020 to INR 629.60 crore in March 2025, but profitability has declined, with profit after tax dropping from INR 61.61 crore in March 2021 to INR 38.55 crore in March 2025 due to rising costs. Total assets increased significantly, while cash flow from operating activities remained positive.

Answer:<BR>The historical performance of Kopran shows a mixed trend in financial metrics over the years, with notable fluctuations in sales, profits, and expenses.<BR><BR>Breakdown:<BR>Kopran's net sales have shown a steady increase from INR 359.50 crore in March 2020 to INR 629.60 crore in March 2025, reflecting a strong growth trajectory. However, the total operating income also increased correspondingly, reaching INR 629.60 crore in March 2025. The raw material costs have risen significantly, from INR 196.19 crore in March 2019 to INR 401.00 crore in March 2025, indicating rising input costs. Operating profit, excluding other income, peaked at INR 99.76 crore in March 2021 but has since declined to INR 72.89 crore in March 2025. Profit before tax followed a similar pattern, reaching a high of INR 83.34 crore in March 2021 before dropping to INR 51.95 crore in March 2025. Consequently, profit after tax also decreased from INR 61.61 crore in March 2021 to INR 38.55 crore in March 2025. The company's total assets have grown from INR 370.21 crore in March 2020 to INR 844.01 crore in March 2025, while total liabilities increased from INR 370.21 crore to INR 147.79 crore over the same period. Cash flow from operating activities remained positive, with INR 41.00 crore in March 2025, although cash flow from investing activities was negative at INR -56.00 crore. Overall, Kopran's financial performance reflects growth in sales and assets but challenges in maintaining profitability amidst rising costs.

Is Kopran technically bullish or bearish?

As of November 12, 2025, Kopran's technical trend has shifted to bearish, supported by negative indicators from MACD, Bollinger Bands, and moving averages, despite a mildly bullish signal from KST on the weekly chart.

As of 12 November 2025, the technical trend for Kopran has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. The MACD is bearish on both the weekly and monthly time frames, and Bollinger Bands also reflect a bearish outlook. Daily moving averages confirm the bearish trend. Although the KST shows a mildly bullish signal on the weekly, the overall monthly trend remains bearish. Dow Theory indicates a mildly bearish stance on both weekly and monthly charts. The stock has experienced significant declines over various time frames, further supporting the bearish sentiment.

Who are the top shareholders of the Kopran?

The top shareholders of Kopran include Oricon Enterprises Limited with 12.88%, individual investors with 42.83%, and Laxminarayan Vyapaar P Ltd at 1.56%. Additionally, there are 29 foreign institutional investors holding 0.76%, and no pledged promoter holdings are reported.

The top shareholders of Kopran include Oricon Enterprises Limited, which holds the highest promoter stake at 12.88%. Additionally, individual investors collectively own 42.83% of the company. Among public shareholders, Laxminarayan Vyapaar P Ltd is notable with a holding of 1.56%. The company also has 29 foreign institutional investors (FIIs) with a combined holding of 0.76%, and there are five mutual fund schemes that hold 0.0%. There are no pledged promoter holdings reported.

Is Kopran overvalued or undervalued?

As of February 12, 2025, Kopran is considered fairly valued with a PE Ratio of 24.22 and has underperformed the Sensex with a return of -18.93%, indicating limited growth expectations compared to its peers.

As of 12 February 2025, Kopran's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as fairly valued. Key ratios include a PE Ratio of 24.22, an EV to EBITDA of 15.13, and a Price to Book Value of 1.80, which suggest that while Kopran is priced reasonably compared to its earnings and book value, it may not present a significant discount to peers.<BR><BR>In comparison to its peers, Kopran's PE Ratio is lower than that of Sun Pharma (35.25) and Divi's Lab (79.33), both categorized as expensive, while it is slightly higher than Cipla (22.99) and Dr. Reddy's Labs (19.49), which are also attractive. Notably, Kopran's PEG Ratio is 0.00, indicating no growth expectations priced into the stock, which could be a concern for potential investors. Over the past year, Kopran has underperformed the Sensex, with a return of -18.93% compared to the Sensex's 7.61%, reinforcing the notion that the stock may not be positioned for significant growth in the near term.

Has Kopran declared dividend?

Kopran Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of September 2, 2024. Despite recent price declines, the company has shown positive long-term returns, with a current dividend yield of 1.55%.

Kopran Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 02 Sep 24<BR><BR>Dividend Yield: 1.55%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -11.22%, with a dividend return of 0%, resulting in a total return of -11.22%.<BR><BR>Over the past year, the price return was -18.86%, the dividend return was 1.26%, leading to a total return of -17.6%.<BR><BR>In the 2-year period, the price return was 8.97%, the dividend return was 3.32%, culminating in a total return of 12.29%.<BR><BR>For the 3-year period, the price return was -13.38%, with a dividend return of 4.89%, resulting in a total return of -8.49%.<BR><BR>In the last 4 years, the price return was -0.42%, the dividend return was 4.99%, leading to a total return of 4.57%.<BR><BR>Over the 5-year period, the price return was 559.45%, with a dividend return of 35.14%, resulting in a total return of 594.59%.<BR><BR>Overall, while Kopran has declared a dividend and has shown positive returns over the long term, recent performance indicates significant declines in price returns, particularly in the shorter time frames. The dividend yield suggests that the company is providing some return to shareholders despite the fluctuations in price.